Denali Therapeutics Inc. (DNLI)
Healthcare
- Fundamental
- 3
- Sentiment
- 4
- Technical
- 2
Do Nothing: technicalScore 2 (weak-bearish bounce-only - price below SMA20/50/200 and EMA21 with MACD -1.08 and ADX 35.8 confirming a strong downtrend) is below the required 3 floor. No pullback/oversold limit qualifies: it would be a countertrend bid (price 20.47 < SMA50 23.38, MACD < 0) into a live short-term downtrend. No breakout/momentum stop qualifies either: there is no momentum structure to break out of - nearest settled resistance 20.65 (Sep-17 high) would mechanically give R/R ~1.15, but the entry fights a strong downtrend and fails the score floor.
Company overview
Denali Therapeutics Inc., founded in 2013 and based in South San Francisco, focuses on developing treatments for neurodegenerative diseases. The company has a robust pipeline, including BIIB122/DNL151 for Parkinson's disease and DNL310 for Hunter syndrome, among others. Denali collaborates with several partners, including Takeda Pharmaceutical and Genentech, to advance its research and development efforts.
Fundamental
fairDenali is moving from development to early commercialization with strong liquidity but remains loss-making.
Denali has entered the early commercial phase with FDA accelerated approval of AVLAYAH and initial product sales, but it is still deeply loss-making with sizable ongoing cash burn. Liquidity is strong (about $940M in cash and marketable securities at 6/30/26 plus a ~$195M priority-review-voucher sale in July 2026), yet near-term upside depends on launch execution and pipeline/confirmatory outcomes rather than current earnings power.
Sentiment
goodMedia tone has improved post-earnings, with positive coverage on AVLAYAH's launch revenue.
Recent coverage has turned modestly positive on Q2 results that highlighted early AVLAYAH launch-revenue traction (announced), improving the media tone versus the prior 30–90d window that was weighed down by the BIIB122 Parkinson’s setback. Red-Flag Screen clean (no regulator-confirmed investigations or material litigation surfaced).
Technical
weakThe stock is in a strong downtrend with only an oversold reflex bounce, lacking a tradeable long setup.
Weak-bearish / bounce-only chart. Price 20.47 closed +4.7% on an above-average volume up-day, but sits BELOW every key moving average (SMA20 22.27, SMA50 23.38, SMA200 20.97, EMA9 20.77, EMA21 21.90), MACD is negative (-1.08) and below its signal (-0.86), and ADX14 35.80 is rising while price falls - a strong DOWN trend, not an uptrend. Bullish elements are bounce mechanics only: RSI14 33.55 turning up off 23.7 oversold, Williams %R -77.22 recovering from -96, histogram narrowing (-0.31 to -0.23). One reflex bounce inside a strong downtrend earns a 2 (bounce-only), below the 3 floor for any bullish entry. A pullback/oversold limit would additionally be countertrend (price < SMA50 with MACD < 0).
You’re looking at 2026-09-21 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.